Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its bispecific antibody (BsAb) Tecvayli (teclistamab) for the treatment of relapsed or refractory multiple myeloma (r/rMM) in patients who have received three or more prior lines of therapy.
Tecvayli, which targets CD3 and BCMA, has already been granted marketing authorization in the U.S. and the European Union (EU). Clinical trials have demonstrated that Tecvayli’s response rate in patients with relapsed or refractory MM, who have been treated with at least three prior lines of therapy, exceeds 60%. Notably, Chinese patients have shown an even higher overall response rate (ORR) of 76.9%.- Flcube.com
